Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Thursday, April 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-04-30): -103.44%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-288.89%
RETURN ON EQUITY (ROE) AVG 3Y
-273.12%
RETURN ON EQUITY (ROE) AVG 5Y
-172.86%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GRI Bio, Inc.
Market Cap
$4.13M
Return on Equity (ROE)
N/A
TTM Avg
-288.89%
3Y Avg
-273.12%
5Y Avg
-172.86%
Market Cap
$4.11M
Return on Equity (ROE)
N/A
TTM Avg
-470.92%
3Y Avg
-382.96%
5Y Avg
-276.61%
Market Cap
$4.23M
Return on Equity (ROE)
-184.04%
TTM Avg
9542.92%
3Y Avg
4740.03%
5Y Avg
3155.09%
Market Cap
$3.97M
Return on Equity (ROE)
-437.15%
TTM Avg
-328.44%
3Y Avg
-188.67%
5Y Avg
-533.64%
Market Cap
$4.28M
Return on Equity (ROE)
-424.89%
TTM Avg
-156.14%
3Y Avg
-97.37%
5Y Avg
-86.32%
Market Cap
$3.87M
Return on Equity (ROE)
-310.33%
TTM Avg
-204.84%
3Y Avg
-115.20%
5Y Avg
-69.88%
Market Cap
$4.47M
Return on Equity (ROE)
-54.15%
TTM Avg
0.37%
3Y Avg
-1.09%
5Y Avg
-10.37%
Market Cap
$4.55M
Return on Equity (ROE)
-239.95%
TTM Avg
-454.28%
3Y Avg
-297.70%
5Y Avg
-194.53%
Market Cap
$3.74M
Return on Equity (ROE)
N/A
TTM Avg
5741.84%
3Y Avg
2797.55%
5Y Avg
1847.94%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRI Bio, Inc. (GRI) | $4.13M | N/A | -288.89% | -273.12% | -172.86% |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.11M | N/A | -470.92% | -382.96% | -276.61% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.23M | -184.04% | 9542.92% | 4740.03% | 3155.09% |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.97M | -437.15% | -328.44% | -188.67% | -533.64% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.28M | -424.89% | -156.14% | -97.37% | -86.32% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.87M | -310.33% | -204.84% | -115.20% | -69.88% |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.47M | -54.15% | 0.37% | -1.09% | -10.37% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | -239.95% | -454.28% | -297.70% | -194.53% |
| Evogene Ltd. (EVGN)vs › | $3.74M | N/A | 5741.84% | 2797.55% | 1847.94% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.75M | -383.03% | -1602.50% | -1094.59% | -783.90% |
ROE
N/A
ROA
N/A
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-04-30 | -103.44% |
| 2026-01-31 | -199.00% |
| 2025-10-31 | -564.22% |
| 2024-10-31 | -225.79% |
| 2022-06-30 | -60.53% |
| 2022-03-31 | -126.07% |
| 2021-12-31 | -112.98% |
| 2021-09-30 | -87.94% |
| 2021-06-30 | -75.75% |
| 2021-03-31 | -52.37% |
| 2020-06-30 | -426.06% |
| 2019-12-31 | -107.80% |
